Alexia Belavgeni

Alexia Belavgeni

Auto-generated profile, based on publicly available information

Alexia Belavgeni

Institute of Clinical Chemistry and Laboratory Medicine, University Hospital Carl Gustav Carus at the Technische Universität Dresden, Dresden, Germany

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 February 2019 in The Journal of Pathology
Verified
Journal Article
Open access
PDF file
WTWulf Tonnus
Wulf Tonnus
CMClaudia Meyer
Claudia Meyer
APAlexander Paliege
Alexander Paliege
ABAlexia Belavgeni
Alexia Belavgeni
AMAnne von Mässenhausen
Anne von Mässenhausen
ALAndreas Linkermann
Andreas Linkermann
Necrosis of a cell is defined by the loss of its plasma membrane integrity. Morphologically, necrosis occurs in several forms such as coagulative necrosis, colliquative necrosis, caseating necrosis, fibrinoid necrosis, and others. Biochemically, necrosis was demonstrated to represent a number of genetically determined signalling pathways. These include (i) kinase‐mediated necroptosis, which depends on receptor interacting protein kinase 3 (RIPK3)‐mediated phosphorylation of the pseudokinase mixed lineage kinase domain like (MLKL); (ii) gasdermin‐mediated necrosis downstream of inflammasomes, also referred to as pyroptosis; and (iii) an iron‐catalysed mechanism of highly specific lipid peroxidation named ferroptosis. Given the molecular understanding of the nature of these pathways, specific antibodies may allow direct detection of regulated necrosis and correlation with morphological features. Necroptosis can be specifically detected by immunohistochemistry and immunofluorescence employing antibodies to phosphorylated MLKL. Likewise, it is possible to generate cleavage‐specific antibodies against epitopes in gasdermin protein family members. In ferroptosis, however, specific detection requires quantification of oxidative lipids by mass spectrometry (oxylipidomics). Together with classical cell death markers, such as TUNEL staining and detection of cleaved caspase‐3 in apoptotic cells, the extension of the arsenal of necrosis markers will allow pathological detection of specific molecular pathways rather than isolated morphological descriptions. These novel pieces of information will be extraordinarily helpful for clinicians as inhibitors of necroptosis (necrostatins), ferroptosis (ferrostatins), and inflammasomes have emerged in clinical trials. Anatomical pathologists should embrace these novel ancillary tests and the concepts behind them and test their impact on diagnostic precision, prognostication, and the prediction of response to the upcoming anti‐necrotic therapies. Copyright © 2019 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

4 February 2022 in Science Advances
Verified
Journal Article
Open access
AMAnne von Mässenhausen
Anne von Mässenhausen
NGNadia Zamora Gonzalez
Nadia Zamora Gonzalez
FMFrancesca Maremonti
Francesca Maremonti
ABAlexia Belavgeni
Alexia Belavgeni
WTWulf Tonnus
Wulf Tonnus
ALAndreas Linkermann
Andreas Linkermann
Dexamethasone is widely used as an immunosuppressive therapy and recently as COVID-19 treatment. Here, we demonstrate that dexamethasone sensitizes to ferroptosis, a form of iron-catalyzed necrosis, previously suggested to contribute to diseases such as acute kidney injury, myocardial infarction, and stroke, all of which are triggered by glutathione (GSH) depletion. GSH levels were significantly decreased by dexamethasone. Mechanistically, we identified that dexamethasone up-regulated the GSH metabolism regulating protein dipeptidase-1 (DPEP1) in a glucocorticoid receptor (GR)–dependent manner. DPEP1 knockdown reversed the phenotype of dexamethasone-induced ferroptosis sensitization. Ferroptosis inhibitors, the DPEP1 inhibitor cilastatin, or genetic DPEP1 inactivation reversed the dexamethasone-induced increase in tubular necrosis in freshly isolated renal tubules. Our data indicate that dexamethasone sensitizes to ferroptosis by a GR-mediated increase in DPEP1 expression and GSH depletion. Together, we identified a previously unknown mechanism of glucocorticoid-mediated sensitization to ferroptosis bearing clinical and therapeutic implications.

13 August 2025 in Nature
Verified
Journal Article
Open access
WTWulf Tonnus
Wulf Tonnus
FMFrancesca Maremonti
Francesca Maremonti
SGShubhangi Gavali
Shubhangi Gavali
MSMarlena Nastassja Schlecht
Marlena Nastassja Schlecht
FGFlorian Gembardt
Florian Gembardt
ALAndreas Linkermann
Andreas Linkermann
Acute tubular necrosis mediates acute kidney injury (AKI) and nephron loss1, the hallmark of end-stage renal disease2-4. For decades, it has been known that female kidneys are less sensitive to AKI5,6. Acute tubular necrosis involves dynamic cell death propagation by ferroptosis along the tubular compartment7,8. Here we demonstrate abrogated ferroptotic cell death propagation in female kidney tubules. 17β-oestradiol establishes an anti-ferroptotic state through non-genomic and genomic mechanisms. These include the potent direct inhibition of ferroptosis by hydroxyoestradiol derivatives, which function as radical trapping antioxidants, are present at high concentrations in kidney tubules and, when exogenously applied, protect male mice from AKI. In cells, the oxidized hydroxyoestradiols are recycled by FSP19,10, but FSP1-deficient female mice were not sensitive to AKI. At the genomic level, female ESR1-deficient kidney tubules partially lose their anti-ferroptotic capacity, similar to ovariectomized mice. While ESR1 promotes the anti-ferroptotic hydropersulfide system, male tubules express pro-ferroptotic proteins of the ether lipid pathway which are suppressed by ESR1 in female tissues until menopause. In summary, we identified non-genomic and genomic mechanisms that collectively explain ferroptosis resistance in female tubules and may function as therapeutic targets for male and postmenopausal female individuals.

16 June 2021 in Nature Reviews Endocrinology
Verified
Journal Article
Closed access
PDF file
WTWulf Tonnus
Wulf Tonnus
ABAlexia Belavgeni
Alexia Belavgeni
FBFelix Beuschlein
Felix Beuschlein
GEGraeme Eisenhofer
Graeme Eisenhofer
MFMartin Fassnacht
Martin Fassnacht
ALAndreas Linkermann
Andreas Linkermann

15 September 2022 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
WTWulf Tonnus
Wulf Tonnus
FMFrancesca Maremonti
Francesca Maremonti
ABAlexia Belavgeni
Alexia Belavgeni
MLMarkus Latk
Markus Latk
YKYoshihiro Kusunoki
Yoshihiro Kusunoki
ALAndreas Linkermann
Andreas Linkermann
Signaling pathways of regulated necrosis, such as necroptosis and ferroptosis, contribute to acute kidney injury (AKI), but the role of pyroptosis is unclear. Pyroptosis is mediated by the pore-forming protein gasdermin D (GSDMD). Here, we report a specific pattern of GSDMD-protein expression in the peritubular compartment of mice that underwent bilateral ischemia and reperfusion injury (IRI). Along similar lines, the GSDMD-protein expression in whole kidney lysates increased during the first 84 h following cisplatin-induced AKI. Importantly, unlike whole kidney lysates, no GSDMD-protein expression was detectable in isolated kidney tubules. In IRI and cisplatin-induced AKI, GSDMD-deficient mice exhibited hypersensitivity to injury as assessed by tubular damage, elevated markers of serum urea, and serum creatinine. This hypersensitivity was reversed by a combined deficiency of GSDMD and the necroptosis mediator mixed lineage kinase domain-like (MLKL). In conclusion, we demonstrate a non-cell autonomous role for GSDMD in protecting the tubular compartment from necroptosis-mediated damage in IRI.